Single center, randomized, double-blind, placebo controlled phase Ib Study to Evaluate tolerability, PK/PD of three doses of Seraprevir in subjects with chronically infected hepatitis C virus

Trial Profile

Single center, randomized, double-blind, placebo controlled phase Ib Study to Evaluate tolerability, PK/PD of three doses of Seraprevir in subjects with chronically infected hepatitis C virus

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Seraprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ginkgo Pharma
  • Most Recent Events

    • 23 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to the results Results presented at The International Liver Congress 2017
    • 29 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top